Disease response and patient-reported outcomes among initiators of ixekizumab. (3rd April 2022)

• Record Type: Journal Article
• Authors: Shahriari, Mona; Harrison, Ryan W.; Burge, Russel; Lin, Chen-Yen; Malatestinic, William N.; Goldblum, Orin M.; McLean, Robert R.; Crabtree, Margaux M.; O'Brien, Jacqueline; Grace, Elsie L.; Murage, Mwangi J.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 3(2022)
• Page Start: 1538
• Page End: 1546
• Publication Date: 2022-04-03
• Subjects: Biologics -- ixekizumab -- psoriasis -- treatment; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2020.1853023
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Objectives: There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes. Methods: Adult patients with psoriasis who initiated ixekizumab and completed a 6-month follow-up visit were enrolled from the Corrona Psoriasis Registry. Disease characteristics and outcomes were assessed at ixekizumab initiation. Outcomes included the mean 6-month change in Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator Global Assessment (IGA), and IGA*BSA. Results: From baseline to follow-up in all patients ( n = 136), means decreased for IGA*BSA (−45.5) and BSA (−12.4), and a higher % achieved an absolute PASI ≤ 5 (84.6%), BSA 0–3 (72.1%), and IGA 0/1 (50.7%). Within stratified groups, means decreased for PASI <12 for IGA*BSA (−21.1) and BSA (−6.3); PASI≥12 for IGA*BSA (−94.8) and BSA (−24.6); weight <100 kg for IGA*BSA (−45.1) and BSA (−12.4); weight ≥100 kg for IGA*BSA (−46.2) and BSA (−12.3); concomitant PsA for IGA*BSA (−56.0) and BSA (−15.3); and in no concomitant PsA for IGA*BSA (−36.9) and BSA (−10.0). Conclusions: We provide real-world evidence on the benefits of ixekizumab for treating psoriasis, regardless of baseline disease severity, weight, or concomitant PsA.